Novartis' serelaxin receives breakthrough designation

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA granted breakthrough therapy designation to serelaxin ( RLX030) to treat acute heart failure (AHF). The pharma also said the recombinant human relaxin 2 (RLN2...